Your cart is empty
Continue shoppingOptical Prism introduces Canadian eye care professionals to Avulux, the world’s first clinically proven lens for migraine and light sensitivity management. The article covers trial results showing 72% of Avulux wearers reported no light sensitivity at hour two of a migraine attack, along with a 36% reduction in abortive medication use.
Elevate patient care with Avulux
White Glove Onboarding
Dedicated Avulux representatives are available to enable you and your team
Trusted by Over 1,400 ECPs
There are over 1,400 Avulux Authorized Providers globally
Ongoing Support & Resources
Avulux providers have access to our team and a suite of tools to help you better serve your patients
Over 50,000
Over 50,000 Avulux wearers are managing the impact of light on their lives.
Indications for Use: Avulux® is an FDA-authorized, over-the-counter precision optical filter indicated to block light at 480 nm (high blue range) and 590 nm (red/amber range), while allowing light in the remaining visible color spectrum through, to decrease the impact of light sensitivity in patients diagnosed with episodic migraine aged 12 years and older. The use of Avulux should not alter the usual care therapy of patients diagnosed with episodic migraine, including medication usage.
Avulux is intended to be used as an adjunct to usual care for migraine, including medication. It is not intended to diagnose, treat, cure, or prevent migraine or any other disease and is not a substitute for professional medical advice, diagnosis, or treatment. Consult a qualified healthcare professional regarding migraine symptoms and treatment. Avulux is classified by the U.S. Food and Drug Administration as a Class I medical device under 21 CFR § 882.5811, product code QEO. De Novo request DEN250026.
